 Hodgkin Disease
"Hodgkin Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
| Descriptor ID |
D006689
|
| MeSH Number(s) |
C04.557.386.355 C15.604.515.569.355 C20.683.515.761.355
|
| Concept/Terms |
Hodgkin Disease- Hodgkin Disease
- Disease, Hodgkin
- Granuloma, Hodgkin's
- Hodgkin's Granuloma
- Granuloma, Hodgkins
- Hodgkins Granuloma
- Lymphogranuloma, Malignant
- Lymphogranulomas, Malignant
- Malignant Lymphogranuloma
- Malignant Lymphogranulomas
- Hodgkin Lymphoma
- Lymphoma, Hodgkin
- Hodgkin's Disease
- Disease, Hodgkin's
- Hodgkin's Lymphoma
- Hodgkins Lymphoma
- Lymphoma, Hodgkin's
- Hodgkins Disease
- Disease, Hodgkins
- Granuloma, Hodgkin
- Hodgkin Granuloma
- Granuloma, Malignant
- Malignant Granuloma
- Malignant Granulomas
|
Below are MeSH descriptors whose meaning is more general than "Hodgkin Disease".
Below are MeSH descriptors whose meaning is more specific than "Hodgkin Disease".
This graph shows the total number of publications written about "Hodgkin Disease" by people in this website by year, and whether "Hodgkin Disease" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 2 | 1 | 3 | | 1998 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 3 | 0 | 3 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2014 | 2 | 0 | 2 | | 2015 | 5 | 1 | 6 | | 2016 | 10 | 0 | 10 | | 2017 | 11 | 0 | 11 | | 2018 | 11 | 0 | 11 | | 2019 | 3 | 0 | 3 | | 2020 | 9 | 1 | 10 | | 2021 | 8 | 0 | 8 | | 2022 | 3 | 0 | 3 | | 2023 | 8 | 0 | 8 | | 2024 | 5 | 0 | 5 | | 2025 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Hodgkin Disease" by people in Profiles.
-
Milgrom SA, Castellino SM. Shifting the Balance of Therapeutic Radiation in Adolescent and Young Adult Hodgkin Lymphoma. Cancer Epidemiol Biomarkers Prev. 2025 Sep 02; 34(9):1445-1447.
-
Hernández-Benítez J, López-Azcarraga A, Flerlage JE, Castellino S, Aristizabal P, Hoppe BS, Milgrom SA, de Paula MJA, Mailhot Vega RB. Curative Treatment of Pediatric Hodgkin Lymphoma With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Consolidation Radiotherapy: A Systematic Review and Suggested Recommendations. JCO Glob Oncol. 2025 Jun; 11:e2400485.
-
Voorhees TJ, McLaughlin EM, Torka P, Florindez J, Kim NH, Moyo TK, Reves H, Sumransub N, Deshpande S, Rose A, Duarte C, Faisal MS, Hamid S, Subbiah S, Ayyappan S, Shea L, Cortese M, Patel K, Major A, Saeed H, Svoboda J, Desai S, Geethakumari PR, Hamadani M, Grover N, Epperla N. Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers. Blood Cancer J. 2025 03 26; 15(1):45.
-
Zhou X, Mould DR, Gore L, Bai X, Gupta N. Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure-Response Analysis. Clin Pharmacol Ther. 2025 Jun; 117(6):1803-1810.
-
Ou JY, Kaddas HK, Alonzo TA, Spector LG, Fallahazad N, Owens E, Collin LJ, Green AL, Kirchhoff AC. Sociodemographic and Socioeconomic Factors Correlate with Late-Stage Pediatric Hodgkin Lymphoma and Rhabdomyosarcoma: A Report from the Children's Oncology Group Registries. Cancer Epidemiol Biomarkers Prev. 2024 Oct 02; 33(10):1327-1338.
-
Lo AC, Parikh RR, Kamdar M, Milgrom SA. At the Cutting Edge: Novel Agents in Hodgkin Lymphoma and the Evolving Role of Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024 Sep 01; 120(1):1-9.
-
Kahn JM, Mauz-Korholz C, Hernandez T, Milgrom SA, Castellino SM. Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision Making. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e432420.
-
Heneghan MB, Belsky JA, Milgrom SA, Forlenza CJ. The pediatric approach to Hodgkin lymphoma. Semin Hematol. 2024 Aug; 61(4):245-252.
-
Binkley MS, Flerlage JE, Savage KJ, Akhtar S, Steiner R, Zhang XY, Dickinson M, Prica A, Major A, Hendrickson PG, Hopkins D, Ng A, Casulo C, Baron J, Roberts KB, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin LJ, Henry M, Smith CM, Halperin D, Brady J, Brennan B, Senchenko MA, Reeves M, Hoppe BS, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes EA, Lee D, Doo NW, Barraclough A, Cheah CY, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer MJ, Eichenauer DA, Hoppe RT. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. J Clin Oncol. 2024 Jul 01; 42(19):2271-2280.
-
Steiner RE, Hwang SR, Khurana A, Habermann TM, Epperla N, Annunzio K, Allen PB, Baird K, Paulino D, Alderuccio JP, Lossos IS, David K, Evens AM, Pandya K, Bair SM, Kamdar M, Ba Aqeel S, Torka P, Lynch R, Smith S, Feng L, Noorani M, Ahmed S, Nair R, Vega F, Wu S, Fang P, Pinnix CC, Gunther JR, Dabaja BS, Lee HJ. Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma. Blood Adv. 2023 12 26; 7(24):7485-7493.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|